Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot
Strategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patients
RESEARCH TRIANGLE PARK, N.C., May 2, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced its partnership with the Digital Medicine Society (DiMe) in support of the CancerX inaugural project. Answering the call of the White House, Science 37 will join DiMe and Moffitt Cancer Center as part of CancerX, a new public-private partnership effort to rapidly accelerate the pace of cancer innovation in the U.S., alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH).
CancerX was recently announced by U.S. President Joe Biden and Dr. Jill Biden as part of the reignited national Cancer Moonshot initiative. It will unite the diverse stakeholders and innovators necessary to unleash the power of innovation to design and create a future that's free of the burden of cancer.
Through this partnership, Science 37 will work with the CancerX project team and participating clinical trial sponsors on the inaugural project, “Advancing Digital Innovation to Improve Equity and Reduce Financial Toxicity in Cancer Care and Research.” This project will further advance remote conduct in oncology trials, including precision medicine, early cancer detection, and long-term follow-up for cell and gene therapy.
“Science 37’s virtual site, the Metasite, is already leading the way to enable access and equity in clinical trials,” said Dr. Shaalan Beg, VP of Oncology at Science 37. “From breast cancer studies requiring at-home administration of anticancer treatment every three weeks that significantly reduced patient burden, to early detection cancer studies where we’ve enrolled more than 24% minority representation with 25,000+ medical records collected; the pace of progress in oncology research that our Metasite enables is unparalleled. Our team brings unique expertise in implementing virtual research tools by engaging patients and oncology practices. We are delighted to support the White House CancerX and Cancer Moonshot initiative to further enable equity in oncology research.”
“We are thrilled to partner with Science 37 on the inaugural project for CancerX to use digital innovation to improve equity and reduce financial toxicity in cancer care and research,” said Sarah Sheehan, DiMe Oncology Program Lead. "Today, cancer is the second leading cause of death in the United States and those with a cancer diagnosis are much more likely to experience an adverse financial event than those without. Our work will unleash the power of digital innovation to democratize access to better quality health and economic outcomes after cancer treatment for a broader coalition of patients."
About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email firstname.lastname@example.org.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.